Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 16 studies | 31% ± 16% | |
endothelial cell | 15 studies | 30% ± 11% | |
macrophage | 10 studies | 22% ± 4% | |
natural killer cell | 9 studies | 18% ± 2% | |
fibroblast | 9 studies | 25% ± 10% | |
adipocyte | 9 studies | 26% ± 6% | |
microglial cell | 8 studies | 24% ± 9% | |
plasmacytoid dendritic cell | 8 studies | 24% ± 9% | |
conventional dendritic cell | 7 studies | 21% ± 5% | |
monocyte | 7 studies | 21% ± 7% | |
glutamatergic neuron | 7 studies | 41% ± 21% | |
epithelial cell | 7 studies | 35% ± 14% | |
B cell | 6 studies | 21% ± 5% | |
retinal rod cell | 6 studies | 27% ± 13% | |
dendritic cell | 6 studies | 27% ± 14% | |
type I pneumocyte | 6 studies | 19% ± 3% | |
CD4-positive, alpha-beta T cell | 5 studies | 16% ± 1% | |
neuron | 5 studies | 28% ± 12% | |
basal cell | 5 studies | 33% ± 15% | |
retinal cone cell | 5 studies | 40% ± 19% | |
endothelial cell of lymphatic vessel | 5 studies | 20% ± 3% | |
oligodendrocyte | 5 studies | 26% ± 10% | |
classical monocyte | 4 studies | 21% ± 5% | |
mature NK T cell | 4 studies | 17% ± 3% | |
retinal ganglion cell | 4 studies | 49% ± 28% | |
pericyte | 4 studies | 22% ± 5% | |
myeloid cell | 4 studies | 23% ± 8% | |
retina horizontal cell | 4 studies | 31% ± 12% | |
ciliated cell | 4 studies | 29% ± 11% | |
GABAergic neuron | 4 studies | 47% ± 16% | |
oligodendrocyte precursor cell | 4 studies | 27% ± 12% | |
interneuron | 4 studies | 39% ± 19% | |
hepatocyte | 4 studies | 45% ± 17% | |
naive B cell | 3 studies | 18% ± 2% | |
retinal bipolar neuron | 3 studies | 32% ± 11% | |
myofibroblast cell | 3 studies | 22% ± 3% | |
smooth muscle cell | 3 studies | 21% ± 5% | |
club cell | 3 studies | 16% ± 1% | |
amacrine cell | 3 studies | 29% ± 15% | |
cardiac muscle cell | 3 studies | 19% ± 1% | |
lymphocyte | 3 studies | 24% ± 5% | |
muscle cell | 3 studies | 22% ± 7% | |
type II pneumocyte | 3 studies | 21% ± 6% | |
enteroendocrine cell | 3 studies | 24% ± 5% | |
intestinal crypt stem cell | 3 studies | 18% ± 1% | |
alveolar macrophage | 3 studies | 21% ± 3% | |
transit amplifying cell | 3 studies | 37% ± 24% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 6822.21 | 1445 / 1445 | 100% | 52.62 | 183 / 183 |
liver | 100% | 5337.59 | 226 / 226 | 100% | 37.11 | 406 / 406 |
lung | 100% | 6403.49 | 578 / 578 | 100% | 49.42 | 1155 / 1155 |
ovary | 100% | 5656.30 | 180 / 180 | 100% | 40.01 | 430 / 430 |
stomach | 100% | 4977.60 | 359 / 359 | 100% | 43.00 | 286 / 286 |
thymus | 100% | 7050.07 | 653 / 653 | 100% | 52.48 | 605 / 605 |
uterus | 100% | 6846.83 | 170 / 170 | 100% | 50.30 | 459 / 459 |
brain | 100% | 6272.26 | 2638 / 2642 | 100% | 58.93 | 705 / 705 |
breast | 100% | 6821.43 | 459 / 459 | 100% | 48.63 | 1116 / 1118 |
intestine | 100% | 6321.37 | 966 / 966 | 100% | 42.98 | 526 / 527 |
prostate | 100% | 6584.85 | 245 / 245 | 100% | 36.06 | 501 / 502 |
skin | 100% | 6538.78 | 1809 / 1809 | 100% | 62.83 | 471 / 472 |
kidney | 100% | 5669.99 | 89 / 89 | 100% | 44.20 | 898 / 901 |
bladder | 100% | 7033.71 | 21 / 21 | 100% | 47.39 | 502 / 504 |
pancreas | 99% | 3148.71 | 326 / 328 | 99% | 38.38 | 177 / 178 |
adrenal gland | 100% | 7927.96 | 258 / 258 | 99% | 41.09 | 227 / 230 |
adipose | 100% | 6825.77 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 6506.06 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 51.80 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 51.86 | 29 / 29 |
muscle | 100% | 6470.61 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 7141.81 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 57.47 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 25.60 | 1 / 1 |
heart | 99% | 4177.49 | 851 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 95% | 4805.73 | 881 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042180 | Biological process | cellular ketone metabolic process |
GO_0022400 | Biological process | regulation of opsin-mediated signaling pathway |
GO_0001701 | Biological process | in utero embryonic development |
GO_0018008 | Biological process | N-terminal peptidyl-glycine N-myristoylation |
GO_0072657 | Biological process | protein localization to membrane |
GO_0005829 | Cellular component | cytosol |
GO_0005886 | Cellular component | plasma membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0018030 | Molecular function | peptidyl-lysine N6-myristoyltransferase activity |
GO_0004379 | Molecular function | glycylpeptide N-tetradecanoyltransferase activity |
GO_0019107 | Molecular function | myristoyltransferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | NMT1 |
Protein name | Glycylpeptide N-tetradecanoyltransferase (EC 2.3.1.97) Glycylpeptide N-tetradecanoyltransferase 1 (EC 2.3.1.97) (Myristoyl-CoA:protein N-myristoyltransferase 1) (HsNMT1) (NMT 1) (Type I N-myristoyltransferase) (Peptide N-myristoyltransferase 1) (Protein-lysine myristoyltransferase NMT1) (EC 2.3.1.-) N-myristoyltransferase 1 (cDNA FLJ54222, highly similar to Glycylpeptide N-tetradecanoyltransferase 1) Glycylpeptide N-tetradecanoyltransferase 1 (EC 2.3.1.97) (Myristoyl-CoA:protein N-myristoyltransferase 1) (Peptide N-myristoyltransferase 1) N-myristoyltransferase 1 Glycylpeptide N-tetradecanoyltransferase 1 (Myristoyl-CoA:protein N-myristoyltransferase 1) (Peptide N-myristoyltransferase 1) |
Synonyms | NMT |
Description | FUNCTION: Adds a myristoyl group to the N-terminal glycine residue of certain cellular and viral proteins . Also able to mediate N-terminal lysine myristoylation of proteins: catalyzes myristoylation of ARF6 on both 'Gly-2' and 'Lys-3' . Lysine myristoylation is required to maintain ARF6 on membranes during the GTPase cycle . . FUNCTION: Adds a myristoyl group to the N-terminal glycine residue of certain cellular proteins. . FUNCTION: Adds a myristoyl group to the N-terminal glycine residue of certain cellular proteins. . FUNCTION: Adds a myristoyl group to the N-terminal glycine residue of certain cellular proteins. . FUNCTION: Adds a myristoyl group to the N-terminal glycine residue of certain cellular proteins. . |
Accessions | ENST00000592782.5 [P30419-1] ENST00000678576.1 ENST00000678332.1 Q96HI4 ENST00000592654.3 [P30419-2] ENST00000543908.5 P30419 ENST00000677949.1 ENST00000585561.5 ENST00000590310.2 K7EN42 B7Z8J4 K7EN82 ENST00000676753.1 ENST00000592654 A0A7I2V4Y5 ENST00000258960.7 [P30419-1] ENST00000587670.2 A0A7I2V5M6 A0A7I2V539 A0A7I2V3M5 A0A7I2V5J6 A0A7I2V3U5 A0A7I2V3X4 ENST00000676828.1 [P30419-1] A4FU65 ENST00000678938.1 [P30419-2] ENST00000590114.6 |